ViroPharma licenses Halozyme's hyaluronidase in pursuit of subcu Cinryze
This article was originally published in Scrip
Under a deal potentially worth $83 million, Halozyme Therapeutics has granted the licensing rights for its recombinant human hyaluronidase enzyme (rHuPH20) technology to ViroPharma, which is using rHuPH20 to develop a subcutaneous formulation of its US FDA-approved hereditary angioedema (HAE) drug Cinryze, a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.